Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.

ABSTRACT:

Background

Temozolomide-induced aplastic anemia (TIAA) is a rare but highly challenging complication of temozolomide (TMZ) therapy. Evidence describing prognosis, clinical characteristics, and treatment of this entity is very limited.

Methods

We performed a multicenter, 22-year observational cohort study of patients with central nervous system (CNS) malignancies treated with temozolomide who developed TIAA, retrospectively analyzing prognosis, complications, and recovery. TIAA was defined using adapted evidence-based severe aplastic anemia criteria incorporating profound cytopenias and a minimum duration (4 weeks) without hematologic recovery.

Results

Of 3821 patients with CNS malignancies receiving TMZ, 34 patients (0.89%) met criteria for TIAA. Onset was rapid, with

SUBMITTER: Park AK 

PROVIDER: S-EPMC9159424 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature